- Home
- STRO vs PRQR Comparison
STRO vs PRQR Comparison
Compare STRO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- PRQR
- Stock Information
- Founded
- STRO 2003
- PRQR 2012
- Country
- STRO United States
- PRQR Netherlands
- Employees
- STRO N/A
- PRQR N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- PRQR Health Care
- Exchange
- STRO Nasdaq
- PRQR Nasdaq
- Market Cap
- STRO 172.8M
- PRQR 309.5M
- IPO Year
- STRO 2018
- PRQR 2014
- Fundamental
- Price
- STRO $1.87
- PRQR $2.64
- Analyst Decision
- STRO Strong Buy
- PRQR Strong Buy
- Analyst Count
- STRO 7
- PRQR 5
- Target Price
- STRO $12.14
- PRQR $7.60
- AVG Volume (30 Days)
- STRO 1.4M
- PRQR 605.4K
- Earning Date
- STRO 11-13-2024
- PRQR 11-07-2024
- Dividend Yield
- STRO N/A
- PRQR N/A
- EPS Growth
- STRO N/A
- PRQR N/A
- EPS
- STRO N/A
- PRQR N/A
- Revenue
- STRO $160,955,000.00
- PRQR $20,506,357.00
- Revenue This Year
- STRO N/A
- PRQR $235.11
- Revenue Next Year
- STRO N/A
- PRQR N/A
- P/E Ratio
- STRO N/A
- PRQR N/A
- Revenue Growth
- STRO 230.90
- PRQR 306.68
- 52 Week Low
- STRO $1.70
- PRQR $1.61
- 52 Week High
- STRO $6.13
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- STRO 28.52
- PRQR 37.43
- Support Level
- STRO $1.70
- PRQR $2.48
- Resistance Level
- STRO $1.93
- PRQR $2.83
- Average True Range (ATR)
- STRO 0.20
- PRQR 0.28
- MACD
- STRO -0.01
- PRQR -0.06
- Stochastic Oscillator
- STRO 12.60
- PRQR 26.01
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.